LSK BioPharma Announces a New Board Member

LSK BioPharma Announces a New Board Member

SALT LAKE CITY, USA, July 23, 2019

LSK BioPharma is pleased to announce the addition of one new member to the Board of Directors: Wook Kim. He is currently a Managing Director of HLB and Next Science, a Korea-based company. He has over 20 years’ experience in corporate financing. He was previously a director of E-Land Group with M&A and Global Financing activity.

About LSK BioPharma

LSKB is a privately-held biopharmaceutical company with offices in Utah, California, and South Korea. LSKB specializes in the clinical development of promising targeted therapies for unmet medical needs in cancer. LSKB’s lead proprietary drug candidate is rivoceranib, a selective VEGFR-2 inhibitor which has demonstrated clinical efficacy in a variety of solid tumors. LSKB can be found on the web at www.lskbiopharma.com.


Contact:

Jenna Choi

Associate Manager, Corporate Strategy

jenna.choi@lskbiopharma.com